Polyketal copolymers: A new acid-sensitive delivery vehicle for treating acute inflammatory diseases

Bioconjugate Chemistry

Volumn 19, Issue 6, 2008, Pages 1164-1169

  Yang, Stephen C ^a   Bhide, Mahesh ^b   Crispe, Ian N ^b   Pierce, Robert H ^b,c   Murthy, Niren ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; CONTROLLED DRUG DELIVERY; DEGRADATION; HYDROLYSIS; HYDROPHILICITY; KINETICS; MACROPHAGES; REACTION KINETICS; TARGETED DRUG DELIVERY;

ACID SENSITIVES; ACID SENSITIVITIES; CAUSES OF DEATH; DEGRADATION PRODUCTS; DELIVERY VEHICLE; DRUG DELIVERY VEHICLES; HYDROLYSIS KINETICS; IMATINIB; INFLAMMATORY DISEASE; MICRO PARTICLES;

DISEASES;

ALANINE AMINOTRANSFERASE; IMATINIB; NANOPARTICLE; PK3;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; BLOOD PH; CONTROLLED STUDY; HYDROLYSIS KINETICS; HYDROPHILICITY; HYDROPHOBICITY; INFLAMMATORY DISEASE; LIVER FAILURE; MACROPHAGE; MALE; MICROENCAPSULATION; MOUSE; NONHUMAN;

EID: 45749089792     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc700442g     Document Type: Article

References (19)

1. Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M. R. (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310.
2. Hudson, L. D., and Steinberg, K. P. (1999) Epidemiology of acute lung injury and ARDS. Chest 116, 74S-a-82.
3. Goodman, R. B., Pugin, J., Lee, J. S., and Matthay, M. A. (2003) Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev. 14, 523-535.
4. O'Grady, J. G., and Schalm, S. W. (1993) Acute liver failure: Redefining the syndromes. Lancet 342, 273.
5. Higuchi, Y., Kawakami, S., Yamashita, F., and Hashida, M. (2007) The potential role of fucosylated cationic liposome/NFκB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials 28, 532-539.
6. Wullaert, A., van Loo, G., Heyninck, K., and BeyaertR. (2007) Hepatic tumor necrosis factor signaling and nuclear factor-κB: Effects on liver homeostasis and beyond. Endocr. Rev. 2006, 0031.
7. Zender, L., Hutker, S., Liedtke, C., Tillmann, H. L., Zender, S., Mundt, B., Waltemathe, M., Gosling, T., Flemming, P., Malek, N. P., Trautwein, C., Manns, M. P., Kuhnel, F., and Kubicka, S. (2003) Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. U.S.A. 100, 7797-7802.
8. Anderson, J. M., and Shive, M. S. (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Delivery Rev. 28, 5.
9. Fu, K., Pack, D. W., Klibanov, A. M., and Langer, R. (2000) Visual evidence of acidic environment within degrading poly-(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 17, 100.
10. Gopferich, A., and Tessmar, J. (2002) Polyanhydride degradation and erosion. Adv. Drug Delivery Rev. 54, 911.
11. Kumar, N., Langer, R. S., and Domb, A. J. (2002) Polyanhydrides: an overview. Adv. Drug Delivery Rev. 54, 889.
12. Heffernan, M. J., and Murthy, N. (2005) Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicle. Bioconjugate Chem. 16, 1340.
13. Lee, S., Yang, S. C., Heffernan, M. J., Taylor, W. R., and Murthy, N. (2007) Polyketal microparticles: a new delivery vehicle for superoxide dismutase. Bioconjugate Chem. 18, 4-7.
14. Kwon, Y. J., Standley, S. M., Goodwin, A. P., Gillies, E. R., and Frechet, J. M. J. (2005) Directed antigen presentation using polymeric microparticulate carriers degradable at lysosomal pH for controlled immune responses. Mol. Pharmaceutics 2, 83-91.
15. Zvosec, D. L., Smith, S. W., McCutcheon, J. R., Spillane, J., Hall, B. J., and Peacock, E. A. (2001) Adverse events, including death, associated with the use of 1,4-butanediol. N. Engl. J. Med. 344, 87-94.
16. Deininger, M. W. N., and Druker, B. J. (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55, 401-423.
17. Wolf, A. M., Wolf, D., Rumpold, H., Ludwiczek, S., Enrich, B., Gastl, G., Weiss, G., and Tilg, H. (2005) The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc. Natl. Acad. Sci. U.S.A. 102, 13622-13627.
18. Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., Rosenzweig, A., Salomon, R. N., Van Etten, R. A., Alroy, J., Durand, J.-B., and Force, T. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12, 908-916.
19. Yeon Hee, P., Hae Jeong, P., Bong-Seog, K., Eunyoung, H., Kyung Hee, J., Seo Hyun, Y., Sung Vin, Y., and Joo-Ho, C. (2006) BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 243, 16-22.